Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
$3.63
+0.3%
$3.13
$0.92
$4.08
$953.38M0.883.16 million shs3.90 million shs
Altimmune, Inc. stock logo
ALT
Altimmune
$4.43
-6.9%
$5.70
$2.90
$11.16
$359.32M0.473.35 million shs6.12 million shs
89BIO stock logo
ETNB
89BIO
$10.22
+0.6%
$9.26
$4.16
$11.84
$1.49B1.281.52 million shs1.31 million shs
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
$1.91
+1.6%
$1.82
$1.33
$2.89
$56.48M1.75413,142 shs631,273 shs
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
$25.08
$9.20
$4.30
$13.66
$1.26B1.531.18 million shs2 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
0.00%-1.23%-9.19%+103.67%+285.27%
Altimmune, Inc. stock logo
ALT
Altimmune
0.00%+36.00%-15.30%+19.60%-28.10%
89BIO stock logo
ETNB
89BIO
0.00%+2.84%-1.07%+84.70%+34.84%
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
0.00%+4.89%-4.55%+29.86%+6.06%
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
0.00%+175.00%+175.00%+175.00%+175.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
4.2524 of 5 stars
3.64.00.04.02.00.80.6
Altimmune, Inc. stock logo
ALT
Altimmune
2.2023 of 5 stars
3.51.00.00.02.41.70.6
89BIO stock logo
ETNB
89BIO
1.5624 of 5 stars
3.51.00.00.01.10.80.6
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
2.1335 of 5 stars
3.51.00.00.00.63.30.6
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
3.20
Buy$6.7585.95% Upside
Altimmune, Inc. stock logo
ALT
Altimmune
3.00
Buy$19.00328.89% Upside
89BIO stock logo
ETNB
89BIO
3.00
Buy$26.43158.60% Upside
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
3.00
Buy$21.00999.48% Upside
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest AKBA, FBIO, ETNB, FLXN, and ALT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/27/2025
Altimmune, Inc. stock logo
ALT
Altimmune
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform ➝ Market Perform
6/27/2025
Altimmune, Inc. stock logo
ALT
Altimmune
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$12.00
6/27/2025
89BIO stock logo
ETNB
89BIO
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (D-) ➝ Sell (D-)
6/11/2025
89BIO stock logo
ETNB
89BIO
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (D-) ➝ Sell (D-)
6/4/2025
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$8.00
5/24/2025
89BIO stock logo
ETNB
89BIO
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (D-) ➝ Sell (D-)
5/10/2025
89BIO stock logo
ETNB
89BIO
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (D-) ➝ Sell (D-)
4/30/2025
89BIO stock logo
ETNB
89BIO
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/28/2025
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/28/2025
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$7.00
4/24/2025
89BIO stock logo
ETNB
89BIO
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (D-) ➝ Sell (D-)
(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
$160.18M5.95N/AN/A($0.23) per share-15.78
Altimmune, Inc. stock logo
ALT
Altimmune
$20K17,965.87N/AN/A$1.74 per share2.55
89BIO stock logo
ETNB
89BIO
N/AN/AN/AN/A$3.34 per shareN/A
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
$57.67M0.98N/AN/A($0.06) per share-31.83
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
$85.55M14.75N/AN/A($0.34) per share-73.76
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
-$69.41M-$0.21N/AN/AN/A-24.51%N/A-18.92%8/6/2025 (Estimated)
Altimmune, Inc. stock logo
ALT
Altimmune
-$95.06M-$1.26N/AN/AN/A-451,200.00%-65.44%-58.43%8/6/2025 (Estimated)
89BIO stock logo
ETNB
89BIO
-$367.08M-$3.38N/AN/AN/AN/A-81.44%-70.17%8/4/2025 (Estimated)
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
-$46M-$2.23N/AN/AN/A-71.24%-4,712.53%-27.67%8/12/2025 (Estimated)
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
-$113.71M-$2.01N/AN/AN/A-100.32%N/A-44.26%N/A

Latest AKBA, FBIO, ETNB, FLXN, and ALT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/4/2025Q2 2025
89BIO stock logo
ETNB
89BIO
-$0.49N/AN/AN/AN/AN/A
5/13/2025Q1 2025
Altimmune, Inc. stock logo
ALT
Altimmune
-$0.35-$0.26+$0.09-$0.26$0.00 million$0.01 million
5/8/2025Q1 2025
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
-$0.03$0.03+$0.06$0.03$44.88 million$57.34 million
5/1/2025Q1 2025
89BIO stock logo
ETNB
89BIO
-$0.50-$0.49+$0.01-$0.49N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
N/AN/AN/AN/AN/A
Altimmune, Inc. stock logo
ALT
Altimmune
N/AN/AN/AN/AN/A
89BIO stock logo
ETNB
89BIO
N/AN/AN/AN/AN/A
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
N/AN/AN/AN/AN/A
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
1.89
2.23
2.02
Altimmune, Inc. stock logo
ALT
Altimmune
N/A
15.85
15.85
89BIO stock logo
ETNB
89BIO
0.06
18.03
18.03
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
1.74
1.72
1.55
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
N/A
4.38
4.05

Institutional Ownership

CompanyInstitutional Ownership
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
33.92%
Altimmune, Inc. stock logo
ALT
Altimmune
78.05%
89BIO stock logo
ETNB
89BIO
N/A
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
96.51%
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
90.01%

Insider Ownership

CompanyInsider Ownership
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
3.00%
Altimmune, Inc. stock logo
ALT
Altimmune
4.10%
89BIO stock logo
ETNB
89BIO
2.80%
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
27.90%
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
9.13%
CompanyEmployeesShares OutstandingFree FloatOptionable
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
430262.64 million254.76 millionOptionable
Altimmune, Inc. stock logo
ALT
Altimmune
5081.11 million77.78 millionOptionable
89BIO stock logo
ETNB
89BIO
40145.98 million141.90 millionOptionable
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
17029.57 million21.32 millionOptionable
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
25750.32 million45.73 millionNo Data

Recent News About These Companies

VIRI Virios Therapeutics, Inc.
Spyre Therapeutics Inc SYRE
PFIZER INC's Net Worth
Flexion/Extension Fluoroscopy of C-Spine is Inadequate
Flexion Mobile: Notice of Annual General Meeting

New MarketBeat Followers Over Time

Media Sentiment Over Time

Akebia Therapeutics stock logo

Akebia Therapeutics NASDAQ:AKBA

$3.63 +0.01 (+0.28%)
As of 04:00 PM Eastern

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Altimmune stock logo

Altimmune NASDAQ:ALT

$4.43 -0.33 (-6.93%)
Closing price 04:00 PM Eastern
Extended Trading
$4.41 -0.02 (-0.45%)
As of 05:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

89BIO stock logo

89BIO NASDAQ:ETNB

$10.22 +0.06 (+0.59%)
As of 04:00 PM Eastern

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.

Fortress Biotech stock logo

Fortress Biotech NASDAQ:FBIO

$1.91 +0.03 (+1.60%)
As of 04:00 PM Eastern

Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

Flexion Therapeutics stock logo

Flexion Therapeutics NASDAQ:FLXN

Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA.